Senseonics (NYSEMKT:SENS) announces that users of the Eversense continuous glucose monitoring (CGM) system who download the new Eversense CGM mobile app can start dosing insulin based on readings from the device without the need of a confirmatory blood glucose measurement from a fingerstick sample.
Shares up 3% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.